Drug Trial Radar · NCT05693129
Pediatric Patients Aged 1 to 6 Years With APDS
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
16
Actual
Start
Aug 30, 2023
Primary completion
Jul 9, 2028
Study completion Oct 28, 2028
Sponsor
- Lead sponsor
- Pharming Technologies B.V.Industry
- Sponsor type
- Industry
- Collaborators
- CMIC Co, Ltd. Japan; Labcorp Central Laboratory; Fortrea; Aixial Group
- First posted
- Jan 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 1 to 6 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Conditions
- APDS
Interventions
LeniolisibDrug
The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I & II: Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs)Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year, plus 30 days
- Part I & II: Change from baseline in clinical laboratory test resultsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
- Part I & II: Change from baseline in vital signsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
- Part I & II: Change from baseline in physical examination findingsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
- Part I & II: Change from baseline in electrocardiograms (ECGs)Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year, plus 30 days
- Part I & II: Change from baseline in growth and physical developmentTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
- Part I & II: Reduction in lymphadenopathy as measured by MRI or low-dose CTTime frame: Part I: Baseline and Day 85 Part II: at Day 252, through study completion, an average of 1 year
- Part I: A Percentage of Inhibition of Unstimulated and Stimulated pAkt Levels in B CellsTime frame: Part I: Baseline, Days 29, 57 and 85
Locations
9 sites in 5 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
National Institutes of Health
Bethesda, Maryland
Rainbow Childrens Hospital
Shaker Heights, Ohio
Texas Children's Hospital
Houston, Texas
Kyoto University Hospital
Kyoto, Japan
Institute of Science Tokyo Hospital
Tokyo, Japan
Hospital Pediátrico de Coimbra da ULS Coimbra UNIDADE LOCAL DE SAÚDE DE COIMBRA
Coimbra, Portugal
Hospital Universitario Virgen del Rocío
Seville, Spain
Great Ormond Street Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.